Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Oncogene ; 34(4): 516-24, 2015 Jan 22.
Article in English | MEDLINE | ID: mdl-24469034

ABSTRACT

Most of the squamous cell carcinomas (SCCs) of the skin and head and neck contain p53 mutations. The presence of p53 mutations in premalignant lesions suggests that they represent early events during tumor progression and additional alterations may be required for SCC development. Here we show that codeletion of the p53 and αv integrin genes in mouse stratified epithelia induced SCCs in 100% of the mice, more frequently and with much shorter latency than deletion of either gene alone. The SCCs that lacked p53 and αv in the epithelial tumor cells exhibited high Akt activity, lacked multiple types of infiltrating immune cells, contained a defective vasculature and grew slower than tumors that expressed p53 or αv. These results reveal that loss of αv in epithelial cells that lack p53 promotes SCC development, but also prevents remodeling of the tumor microenvironment and delays tumor growth. We observed that Akt inactivation in SCC cells that lack p53 and αv promoted anoikis. Thus, tumors may arise in these mice as a result of the increased cell survival induced by Akt activation triggered by loss of αv and p53, and by the defective recruitment of immune cells to these tumors, which may allow immune evasion. However, the defective vasculature and lack of a supportive stroma create a restrictive microenvironment in these SCCs that slows their growth. These mechanisms may underlie the rapid onset and slow growth of SCCs that lack p53 and αv.


Subject(s)
Carcinoma, Squamous Cell/etiology , Integrin alphaV/physiology , Proto-Oncogene Proteins c-akt/physiology , Tumor Microenvironment , Tumor Suppressor Protein p53/physiology , Animals , Carcinoma, Squamous Cell/pathology , MAP Kinase Signaling System , Mice , Mouth Neoplasms/etiology , Skin Neoplasms/etiology
2.
Oncogene ; 31(21): 2680-90, 2012 May 24.
Article in English | MEDLINE | ID: mdl-21963848

ABSTRACT

Clinical observations, as well as data obtained from the analysis of genetically engineered mouse models, firmly established the gain-of-function (GOF) properties of certain p53 mutations. However, little is known about the underlying mechanisms. We have used two independent microarray platforms to perform a comprehensive and global analysis of tumors arising in a model of metastatic skin cancer progression, which compares the consequences of a GOF p53(R172H) mutant vs p53 deficiency. DNA profiling revealed a higher level of genomic instability in GOF vs loss-of-function (LOF) p53 squamous cell carcinomas (SCCs). Moreover, GOF p53 SCCs showed preferential amplification of Myc with a corresponding increase in its expression and deregulation of Aurora Kinase A. Fluorescent in situ hybridization confirmed amplification of Myc in primary GOF p53 SCCs and its retention in metastatic tumors. We also identified by RNA profiling distinct gene expression profiles in GOF p53 tumors, which included enriched integrin and Rho signaling, independent of tumor stage. Thus, the progression of GOF p53 papillomas to carcinoma was marked by the acquisition of epithelial-to-mesenchymal transition and metastatic signatures. In contrast, LOF p53 tumors showed enrichment of genes associated with cancer proliferation and chromosomal instability. Collectively, these observations suggest that genomic instability has a prominent role in the early stages of GOF p53 tumor progression (that is, papillomas), whereas it is implicated at a later stage in LOF p53 tumors (that is, SCCs). This model will allow us to identify specific targets in mutant p53 SCCs, which may lead to the development of new therapeutic agents for the treatment of metastatic SCCs.


Subject(s)
Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/secondary , Genes, myc , Mutation , Papilloma/genetics , Protein Serine-Threonine Kinases/metabolism , Skin Neoplasms/genetics , Tumor Suppressor Protein p53 , Animals , Aurora Kinase A , Aurora Kinases , Disease Models, Animal , Disease Progression , Epithelial-Mesenchymal Transition , Gene Amplification , Genomic Instability , Integrins/genetics , Mice , Skin Neoplasms/pathology , Up-Regulation
3.
J Membr Biol ; 215(2-3): 125-33, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17563824

ABSTRACT

Lipopolysaccharide (LPS) is an endotoxin causing sepsis. Studies from our laboratory revealed impaired intestinal absorption of L-leucine and D-fructose in LPS-treated rabbits. The aim of this study was to examine intestinal D-galactose transport following intravenous administration of LPS in the rabbit and to identify the cellular mechanisms driving this process. Endotoxin treatment diminished the buildup of D-galactose in intestinal tissue, the mucosal to serosal transepithelial flux of the sugar and its uptake by brush border membrane vesicles (BBMVs). Intracellular signaling pathways associated with protein kinase C (PKC), protein kinase A (PKA), p38 mitogen-activated protein kinase (p38MAPK), Jun N-terminal kinase (JNK), MAPK/extracellular signal-regulated kinases 1 and 2 (MEK1/2) and proteasome were found to be involved in this reduction in sugar uptake. Na(+)/glucose cotransporter 1 (SGLT1) protein levels in BBMVs were lower for LPS-treated animals than control animals. These findings indicate that LPS inhibits the intestinal absorption of D-galactose via a complex cellular mechanism that could involve posttranscriptional regulation of the SGLT1 transporter.


Subject(s)
Endotoxemia/metabolism , Galactose/metabolism , Intestinal Mucosa/metabolism , Animals , Biological Transport/drug effects , Blotting, Northern , Blotting, Western , Butadienes/pharmacology , Endotoxemia/chemically induced , Galactose/pharmacokinetics , Imidazoles/pharmacology , Intestines/drug effects , Lipopolysaccharides/administration & dosage , Lipopolysaccharides/pharmacology , Male , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Nitriles/pharmacology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Pyridines/pharmacology , Rabbits , Sodium-Glucose Transporter 1/genetics , Sodium-Glucose Transporter 1/metabolism
4.
J Cell Biochem ; 101(1): 99-111, 2007 May 01.
Article in English | MEDLINE | ID: mdl-17177295

ABSTRACT

Sepsis is a systemic response to infection in which toxins, such as bacterial lipopolysaccharide (LPS), stimulate the production of inflammatory mediators like the cytokine tumor necrosis factor alpha (TNF-alpha). Previous studies from our laboratory have revealed that LPS inhibits the intestinal absorption of L-leucine and D-fructose in rabbit when it was intravenously administered, and that TNF-alpha seems to mediate this effect on amino acid absorption. To extend this work, the present study was designed to evaluate the possible effect of TNF-alpha on D-galactose intestinal absorption, identify the intracellular mechanisms involved and establish whether this cytokine mediates possible LPS effects. Our findings indicate that TNF-alpha decreases D-galactose absorption both in rabbit intestinal tissue preparations and brush-border membrane vesicles. Western blot analysis revealed reduced amounts of the Na+/glucose cotransporter (SGLT1) protein in the plasma membrane attributable to the cytokine. On the contrary, TNF-alpha increased SGLT1 mRNA levels. Specific inhibitors of the secondary messengers PKC, PKA, the MAP kinases p38 MAP, JNK, MEK1/2 as well as the proteasome, diminished the TNF-alpha-evoked inhibitory effect. LPS inhibition of the uptake of the sugar was blocked by a TNF-alpha antagonist. In conclusion, TNF-alpha inhibits D-galactose intestinal absorption by decreasing the number of SGLT1 molecules at the enterocyte plasma membrane through a mechanism in which several protein-like kinases are involved.


Subject(s)
Galactose/antagonists & inhibitors , Intestinal Absorption/drug effects , Intestines/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Animals , Anthracenes/administration & dosage , Anthracenes/pharmacology , Blotting, Northern , Blotting, Western , Cell Membrane/drug effects , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Imidazoles/administration & dosage , Imidazoles/pharmacology , Indoles/administration & dosage , Indoles/pharmacology , Injections, Intravenous , Intestinal Absorption/physiology , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , Lipopolysaccharides/pharmacology , Male , Maleimides/administration & dosage , Maleimides/pharmacology , Microvilli/drug effects , Microvilli/metabolism , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3/antagonists & inhibitors , Peptides/administration & dosage , Peptides/pharmacology , Proteasome Inhibitors , Protein Kinase C/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Pyridines/administration & dosage , Pyridines/pharmacology , RNA, Messenger/metabolism , Rabbits , Sepsis/metabolism , Sodium-Glucose Transporter 1/metabolism , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
5.
Clín. investig. arterioscler. (Ed. impr.) ; 17(2): 82-93, mar.-abr. 2005. tab
Article in Es | IBECS | ID: ibc-037862

ABSTRACT

La presente revisión aborda el metabolismo lipoproteico comparado y la inducción de la aterosclerosis con sus controversias en varios modelos animales pertenecientes a un amplio espectro evolutivo que abarca desde los roedores (ratón, conejo, rata, hámster, cobaya), las aves (paloma), los cetartiodáctilos (cerdo) y los carnívoros (perro) hasta los primates (macacos, Rhesus, mono verde africano) (AU)


Current review presents an overview of the compared lipoprotein metabolism and atherosclerosis development and their controversies in several animal models covering a wide phylogenetic spectrum. Orders are rodents (mice, rabbits, rats, hamsters, guinea pigs), birds (pigeons), cetartiodactyla (pigs), carnivores (dogs) and primates (macaques, Rhesus, African green monkey) (AU)


Subject(s)
Rabbits , Rats , Dogs , Mice , Guinea Pigs , Cricetinae , Animals , Animal Experimentation , Arteriosclerosis/diet therapy , Arteriosclerosis/diagnosis , Arteriosclerosis/metabolism , Lipoproteins/metabolism , Hypercholesterolemia/diet therapy , Hypercholesterolemia/metabolism , Primates/genetics , Primates/metabolism , Birds/metabolism , Cholesterol/analysis , Cholesterol/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...